Shares of telehealth provider Hims & Hers Health Inc. extended their recent gains in Thursday's premarket trading, rising 5.1% to $27.19. This advance builds on a significant 10.3% surge during Wednesday's regular session, which closed at $25.88, marking the stock's fourth consecutive day of positive momentum.
A Strategic Shift in Weight-Loss Offerings
The rally is directly tied to a major strategic development. The company has reached a new agreement with pharmaceutical giant Novo Nordisk, effectively settling an ongoing patent dispute. As a result, FDA-approved weight-loss and diabetes medications Wegovy and Ozempic will return to the Hims & Hers digital platform later this month. This move signals a strategic pivot, with the company planning to largely discontinue its compounded semaglutide offerings in favor of these established, branded drugs.
Wall Street Reacts with Upgraded Targets
The settlement has prompted a notable shift in analyst sentiment. Bank of America upgraded its rating on Hims & Hers to neutral from underperform, dramatically raising its price target to $23 from $12.50. Similarly, Citigroup moved to a neutral stance with a $24 target. Deutsche Bank also increased its price target following the truce, which alleviates certain legal overhangs that had concerned investors.
Analysts view the deal favorably on multiple fronts. BTIG's David Larsen described it as "clearly positive," highlighting that it avoids a protracted and uncertain court battle, as well as potential regulatory intervention from bodies like the FDA or the Department of Justice. Truist's Jailendra Singh noted that "mutual necessity" ultimately brought both parties to an agreement after months of tension.
Growth Opportunities and Financial Context
For Hims & Hers, the agreement represents more than just legal closure. CEO Andrew Dudum pointed to "tremendous growth opportunities" stemming from an expanded portfolio of branded GLP-1 drugs. The company anticipates that more affordable cash prices for these medications will help capture the self-pay market segment. This aligns with Novo Nordisk's recent strategy to reduce some U.S. list prices for its weight-loss drugs to a range of $149 to $299, a competitive move against rival Eli Lilly.
The stock's rebound follows a period of weakness. For the full year 2025, Hims & Hers reported revenue of approximately $2.35 billion, net income of $128 million, and a subscriber base exceeding 2.5 million. However, the company's first-quarter revenue guidance of $600 million to $625 million fell short of analyst expectations. Executives attributed the softer outlook to higher product costs within its weight-loss segment.
Potential Headwinds and Regulatory Scrutiny
Despite the bullish narrative, several challenges remain. Analysts have cautioned that while sales of Novo Nordisk's branded drugs are likely to boost top-line revenue, they may come with slimmer profit margins compared to the compounded versions they are replacing. There is also skepticism about whether Hims & Hers can attract enough new subscribers for the branded drugs to fully offset the business it is walking away from.
Adding a layer of complexity, the company's 2025 annual report disclosed an ongoing investigation by the Securities and Exchange Commission into its past statements regarding compounded semaglutide. Furthermore, the U.S. Department of Health and Human Services has made a referral to the Department of Justice concerning potential violations connected to those products.
The imminent rollout of Wegovy (in both pill and injectable forms) and Ozempic injections on the Hims & Hers platform before month-end is now a focal point for investors. This week's sharp stock appreciation places intense scrutiny on this launch, positioning it as a critical test. The market is evaluating whether a straightforward, branded weight-loss strategy can sustainably support the share price without triggering the kind of regulatory backlash that negatively impacted the stock back in February.
